Section snippets

Clinical trial number:

not applicable.

Conflict of interest:

Edo Dongelmans has no conflicts of interests; Milan Sonneveld receives speakers’ fees and research support from Roche, Bristol Myers Squibb, Gilead Sciences, and Fujirebio. Harry Janssen received grants from: Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc. and is consultant for: Aligos, Gilead Sciences, GlaxoSmithKline, Janssen, Roche, Vir Biotechnology Inc., Precision Biosciences, Griffols.

Financial support:

No funding was received for this article.

Author contributions:

Edo Dongelmans, MD (Conceptualization: Equal; Writing – original draft: Lead). Milan Sonneveld, MD, PhD (Conceptualization: Equal; Writing – review & editing: Equal). Harry L.A. Janssen, MD, PhD (Conceptualization: Equal; Supervision: Lead; Writing – review & editing: Equal).

Data availability statement:

not applicable.Nucleo(s)tide analogues (NA) are well-tolerated and highly effective in suppressing HBV DNA in patients with chronic hepatitis B (CHB). Unfortunately, the risk of HCC may persist, particularly in patients who do not achieve functional cure, defined as loss of HBsAg loss. As functional cure is rarely achieved with NA mono-therapy,¹ alternative strategies are explored to increase HBsAg clearance.Recent trials with novel compounds suggest that immune modulatory agents likely play a

中文翻译：

---

提高核苷类似物停用后的功能固化率：peg-IFN 是答案吗？

 部分片段

 临床试验编号：

 不適用。

 利益冲突：

Edo Dongelmans 没有利益冲突;Milan Sonneveld 从罗氏、百时美施贵宝、吉利德科学和 Fujirebio 获得演讲费和研究支持。Harry Janssen 获得了以下机构的资助：吉利德科学、葛兰素史克、杨森、罗氏、Vir Biotechnology Inc.，并担任以下机构的顾问：Aligos、吉利德科学、葛兰素史克、杨森、罗氏、Vir Biotechnology Inc.、Precision Biosciences、Griffols。

 资金支持：

本文未收到任何资金。

 作者贡献：

Edo Dongelmans，医学博士（概念化：相等;写作 – 原始草稿：Lead）。Milan Sonneveld，医学博士，博士（概念化：平等;写作 - 审查和编辑：相等）。Harry L.A. Janssen，医学博士，博士（概念化：相等;监督：领导;写作 - 审查和编辑：相等）。

数据可用性声明：

不適用。核苷类似物 （NA） 耐受性良好，对抑制慢性乙型肝炎 （CHB） 患者的 HBV DNA 非常有效。不幸的是，HCC 的风险可能会持续存在，尤其是在未实现功能性治愈（定义为 HBsAg 损失消失）的患者中。由于 NA 单药治疗很少能实现功能性治愈^，因此探索了提高 HBsAg 清除率的替代策略1。最近对新型化合物的试验表明，免疫调节剂可能起到